Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Fate, Stemgent platform reprograms mature cells as stem cells

Executive Summary

Fate Therapeutics (stem cell biology aimed at modulating cell fate; has a late-preclinical candidate in hematopoietic reconstitution) and Stemgent (reagents for stem cell generation) are creating a program called Catalyst that will offer pharma and biotech clients a platform for drug discovery and development. The technique creates iPS cells--induced pluripotent stem cells--and then re-differentiates them into distinct cell types.
Deal Industry
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Services
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies